New Chloramphenicol Derivatives from the Viewpoint of Anticancer and Antimicrobial Activity
- PMID: 30699905
- PMCID: PMC6466596
- DOI: 10.3390/antibiotics8010009
New Chloramphenicol Derivatives from the Viewpoint of Anticancer and Antimicrobial Activity
Abstract
Over the last years, we have been focused on chloramphenicol conjugates that combine in their structure chloramphenicol base with natural polyamines, spermine, spermidine and putrescine, and their modifications. Conjugate 3, with spermidine (SPD) as a natural polyamine linked to chloramphenicol base, showed the best antibacterial and anticancer properties. Using 3 as a prototype, we here explored the influence of the antibacterial and anticancer activity of additional benzyl groups on N1 amino moiety together with modifications of the alkyl length of the aminobutyl fragment of SPD. Our data demonstrate that the novel modifications did not further improve the antibacterial activity of the prototype. However, one of the novel conjugates (4) showed anticancer activity without affecting bacterial growth, thus emerging as a promising anticancer agent, with no adverse effects on bacterial microflora when taken orally.
Keywords: Chloramphenicol; antibiotics; anticancer activity; antimicrobial activity; conjugates; mitochondrial ribosome; molecular dynamics simulations; polyamines; protein biosynthesis.
Conflict of interest statement
The authors declare no conflict of interest.
Figures






References
-
- Dinos G., Athanassopoulos C., Missiri D., Giannopoulou P., Vlachogiannis I., Papadopoulos G., Papaioannou D., Kalpaxis D. Chloramphenicol Derivatives as Antibacterial and Anticancer Agents: Historic Problems and Current Solutions. Antibiotics. 2016;5:20. doi: 10.3390/antibiotics5020020. - DOI - PMC - PubMed
-
- Lamb R., Ozsvari B., Lisanti C.L., Tanowitz H.B., Howell A., Martinez-Outschoorn U.E., Sotgia F., Lisanti M.P. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease. Oncotarget. 2015;6:4569–4584. doi: 10.18632/oncotarget.3174. - DOI - PMC - PubMed
-
- Marks J., Kannan K., Roncase E.J., Klepacki D., Kefi A., Orelle C., Vázquez-Laslop N., Mankin A.S. Context-specific inhibition of translation by ribosomal antibiotics targeting the peptidyl transferase center. Proc. Natl. Acad. Sci. USA. 2016;113:12150–12155. doi: 10.1073/pnas.1613055113. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources